Business news, market intelligence, and global industry analysis.
The Latest

Lupin subsidiary gets FDA approval for Fluocinolone Acetonide Oil

byPallavi Madhiraju
August 9, 2023
Total
0
Shares
0
0
0

Lupin Limited said that their wholly-owned US subsidiary, Novel Laboratories Inc., has secured approval from the US Food and Drug Administration (US FDA) for its Abbreviated New Drug Application (ANDA) for Fluocinolone Acetonide Oil, 0.01% (Body Oil). This product stands as the generic counterpart to DermaSmoothe/FS 0.01% (Body Oil) originally by Hill Dermaceuticals, Inc.

Commercial Impact and Production Details:

The market value of Fluocinolone Acetonide Oil, tracing back to its reference listed drug Derma-Smoothe/FS®, was approximated at annual sales of USD 10 million in the U.S. as per IQVIA MAT June 2023 figures. Reinforcing the announcement’s significance, Lupin divulged that the production of this approved product will be overseen at their dedicated Somerset facility in the US.

Discover more from Business-News-Today.com

Subscribe to get the latest posts sent to your email.

See also  Botanical Solution Inc. raises additional $7m in Series A funding round
Total
0
Shares
Share 0
Tweet 0
Pin it 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Amgen to acquire Celgene psoriasis drug Otezla for $13.4bn

Amgen acquisition of Otezla : Amgen has agreed to acquire global rights to Celgene’s psoriasis drug Otezla (apremilast) for $13.4 billion, which includes $2.2 billion in expected future cash tax benefits. The deal is being executed to pave way for regulatory approval for the previously announced Bristol-Myers Squibb acquisition of Celgene in a deal worth […]

The post Amgen to acquire Celgene psoriasis drug Otezla for $13.4bn appeared first on PharmaNewsDaily.com.

bypharmanewsdaily